HER-2 signaling and inhibition in breast cancer.

  title={HER-2 signaling and inhibition in breast cancer.},
  author={Brigid C. Browne and Neil A. O'Brien and Michael J. Duffy and John Crown and Norma O'Donovan},
  journal={Current cancer drug targets},
  volume={9 3},
Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of many anti-cancer therapeutic approaches. Trastuzumab (Herceptin), a humanized monoclonal antibody directed against the extracellular domain of HER-2, was the first FDA-approved HER-2… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 43 extracted citations

DNA Mutations May Not Be the Cause of Cancer

Oncology and therapy • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…